封面
市场调查报告书
商品编码
1755829

血清分离凝胶市场成长、规模和趋势分析:产品、最终用户 - 区域展望、竞争策略和细分预测(至 2034 年)

Serum Separation Gel Market Growth, Size, Trends Analysis - By Product, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 250 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到 2034 年全球血清分离凝胶市场规模将达到 160.5 亿美元,复合年增长率为 7.16%。

血清分离胶是一种专用物质,用于在离心过程中将血清从全血中分离出来,并存放在采血管中。它通常由硅胶或惰性聚合物等凝胶材料构成,位于血清与促凝血剂层或抗凝血剂层之间。在离心过程中,凝胶充当屏障,将血球成分与血清物理隔离。

阻碍因素:含有血清分离胶的产品(尤其是采血管)价格高昂,会对医疗机构带来沉重的财务负担。尤其是在资源匮乏的医疗系统和资金不足的机构中,购买这些昂贵的产品可能会对实验室设备、诊断工具和医疗服务的预算造成压力,从而限制关键检测能力的取得。

本报告调查了全球血清分离凝胶市场,并总结了市场概况、市场影响因素和市场机会分析、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局以及主要企业的概况。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场动态

  • 驱动因素、阻碍因素、机会与挑战分析

第五章 市场变数与展望

  • SWOT分析
  • PESTEL分析
  • 波特五力分析
  • 热图分析

第六章 竞争态势

  • 製造地、销售区域、产品类型分布
  • 併购、合作伙伴关係、产品发布和合作

第七章全球血清分离凝胶市场(依产品)

  • 无需采血管的血清分离胶
  • 血清分离胶及采血管

第八章全球血清分离凝胶市场(依最终用户)

  • 医院
  • 血库
  • 製药公司
  • 其他的

第九章全球血清分离凝胶市场

  • 全球市场规模和市场占有率

第 10 章全球血清分离凝胶市场(按地区)

  • 亚太地区
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他的
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • UAE
    • 卡达
    • 南非
    • 埃及
    • 摩洛哥
    • 奈及利亚
    • 其他的
  • 北美洲
    • 加拿大
    • 墨西哥
    • 美国
  • 拉丁美洲
    • 阿根廷
    • 巴西
    • 其他的

第十一章 公司简介

  • Becton, Dickinson and Company
  • BIOSIGMA SpA
  • Bio-Rad Laboratories, Inc
  • Cardinal Health, Inc.
  • Danaher Corporation
  • FL MEDICAL srl
  • Greiner AG
  • Inter Vac Technology
  • Qiagen NV
  • Sekisui Chemical CO., LTD
  • 其他的

第十二章 结论

第十三章简称表

第 14 章参考链接

简介目录
Product Code: HLCA25143

Serum Separation Gel Market Introduction and Overview

According to SPER market research, 'Global Serum Separation Gel Market Size- By Product, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Serum Separation Gel Market is predicted to reach 16.05 billion by 2034 with a CAGR of 7.16%.

Serum separation gel is a specialised substance found in blood collection tubes that helps to separate serum from whole blood during centrifugation. It is often made of gel materials such as silicone or inert polymers and positioned between the serum-free media layer and the clot activator or anticoagulant layer within the tube. During centrifugation, the gel serves as a barrier that separates serum from blood cells.

Restraints: The high cost of serum separation gel items, including blood collection tubes containing the gel, can place a considerable financial burden on healthcare facilities, especially in resource-constrained or underfunded systems. Purchasing serum separation gel solutions at high prices may put a strain on budgets for laboratory supplies, diagnostics, and healthcare services, limiting access to important testing capabilities.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Product, By End User

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered Becton, Dickinson and Company, BIOSIGMA S.p.A, Bio-Rad Laboratories, Inc, Cardinal Health, Inc, Danaher Corporation, FL MEDICAL s.r.l, Greiner AG, InterVacTechnology, Qiagen N.V, Sekisui Chemical CO., LTD.

Global Serum Separation Gel Market Segmentation:

By Product: Based on the Product, Global Serum Separation Gel Market is segmented as; Serum Separation Gel Without Integrated Tubes, Serum Separation Gel with Integrated Tubes.

By End-User: Based on the End-User, Global Serum Separation Gel Market is segmented as; Hospitals, Blood Banks, Pharmaceutical Companies.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTER's Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Serum Separation Gel Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Serum Separation Gel Market

7. Global Serum Separation Gel Market, By Product (USD Million) 2021-2034

  • 7.1. Serum separation gel without integrated tubes
  • 7.2. Serum separation gel with integrated tubes

8. Global Serum Separation Gel Market, By End-User (USD Million) 2021-2034

  • 8.1. Hospitals
  • 8.2. Blood banks
  • 8.3. Pharmaceutical companies
  • 8.4. Other end-users

9. Global Serum Separation Gel Market, (USD Million) 2021-2034

  • 9.1. Global Serum Separation Gel Market Size and Market Share

10. Global Serum Separation Gel Market, By Region, (USD Million) 2021-2034

  • 10.1. Asia-Pacific
    • 10.1.1. Australia
    • 10.1.2. China
    • 10.1.3. India
    • 10.1.4. Japan
    • 10.1.5. South Korea
    • 10.1.6. Rest of Asia-Pacific
  • 10.2. Europe
    • 10.2.1. France
    • 10.2.2. Germany
    • 10.2.3. Italy
    • 10.2.4. Spain
    • 10.2.5. United Kingdom
    • 10.2.6. Rest of Europe
  • 10.3. Middle East and Africa
    • 10.3.1. Kingdom of Saudi Arabia
    • 10.3.2. United Arab Emirates
    • 10.3.3. Qatar
    • 10.3.4. South Africa
    • 10.3.5. Egypt
    • 10.3.6. Morocco
    • 10.3.7. Nigeria
    • 10.3.8. Rest of Middle-East and Africa
  • 10.4. North America
    • 10.4.1. Canada
    • 10.4.2. Mexico
    • 10.4.3. United States
  • 10.5. Latin America
    • 10.5.1. Argentina
    • 10.5.2. Brazil
    • 10.5.3. Rest of Latin America

11. Company Profile

  • 11.1. Becton, Dickinson and Company
    • 11.1.1. Company details
    • 11.1.2. Financial outlook
    • 11.1.3. Product summary
    • 11.1.4. Recent developments
  • 11.2. BIOSIGMA S.p.A
    • 11.2.1. Company details
    • 11.2.2. Financial outlook
    • 11.2.3. Product summary
    • 11.2.4. Recent developments
  • 11.3. Bio-Rad Laboratories, Inc
    • 11.3.1. Company details
    • 11.3.2. Financial outlook
    • 11.3.3. Product summary
    • 11.3.4. Recent developments
  • 11.4. Cardinal Health, Inc.
    • 11.4.1. Company details
    • 11.4.2. Financial outlook
    • 11.4.3. Product summary
    • 11.4.4. Recent developments
  • 11.5. Danaher Corporation
    • 11.5.1. Company details
    • 11.5.2. Financial outlook
    • 11.5.3. Product summary
    • 11.5.4. Recent developments
  • 11.6. FL MEDICAL s.r.l
    • 11.6.1. Company details
    • 11.6.2. Financial outlook
    • 11.6.3. Product summary
    • 11.6.4. Recent developments
  • 11.7. Greiner AG
    • 11.7.1. Company details
    • 11.7.2. Financial outlook
    • 11.7.3. Product summary
    • 11.7.4. Recent developments
  • 11.8. Inter Vac Technology
    • 11.8.1. Company details
    • 11.8.2. Financial outlook
    • 11.8.3. Product summary
    • 11.8.4. Recent developments
  • 11.9. Qiagen N.V
    • 11.9.1. Company details
    • 11.9.2. Financial outlook
    • 11.9.3. Product summary
    • 11.9.4. Recent developments
  • 11.10. Sekisui Chemical CO., LTD
    • 11.10.1. Company details
    • 11.10.2. Financial outlook
    • 11.10.3. Product summary
    • 11.10.4. Recent developments
  • 11.11. Others

12. Conclusion

13. List of Abbreviations

14. Reference Links